CD8A and non-small cell lung carcinoma: In terms of advanced NSCLC, several studies have found that differential types of TME, based on PD-L1 expression and CD8+ TILs or CD68+ macrophages, could accurately predict treatment responses and survival in ICI monotherapy [31–33].